Cosmos Health (NASDAQ:COSM) CEO Grigorios Siokas Purchases 349,825 Shares of Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas acquired 349,825 shares of the company’s stock in a transaction on Thursday, July 30th. The stock was acquired at an average price of $0.20 per share, with a total value of $69,965.00. Following the purchase, the chief executive officer directly owned 14,597,917 shares in the company, valued at approximately $2,919,583.40. This represents a 2.46% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Grigorios Siokas also recently made the following trade(s):

• On Wednesday, July 29th, Grigorios Siokas acquired 766,284 shares of Cosmos Health stock. The stock was acquired at an average cost of $0.18 per share, with a total value of $137,931.12.
• On Thursday, June 11th, Grigorios Siokas bought 218,447 shares of Cosmos Health stock. The shares were acquired at an average price of $0.21 per share, for a total transaction of $45,873.87.
• On Wednesday, June 10th, Grigorios Siokas bought 701,447 shares of Cosmos Health stock. The shares were acquired at an average cost of $0.23 per share, for a total transaction of $161,332.81.

Cosmos Health Stock Performance

Shares of COSM traded up $0.01 during mid-day trading on Friday, hitting $0.21. 2,337,489 shares of the company’s stock were exchanged, compared to its average volume of 4,600,464. The company has a quick ratio of 0.92, a current ratio of 1.08 and a debt-to-equity ratio of 0.31. Cosmos Health Inc. has a 52 week low of $0.16 and a 52 week high of $1.32. The stock’s 50-day simple moving average is $0.23 and its 200-day simple moving average is $0.33. The firm has a market cap of $12.55 million, a price-to-earnings ratio of -0.33 and a beta of 4.83.

Cosmos Health (NASDAQ:COSM) last issued its quarterly earnings results on Wednesday, May 20th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). Cosmos Health had a negative return on equity of 52.85% and a negative net margin of 30.41%.The business had revenue of $18.40 million during the quarter, compared to analysts’ expectations of $17.93 million. On average, equities research analysts expect that Cosmos Health Inc. will post 0.01 EPS for the current year.

Institutional Trading of Cosmos Health

Several large investors have recently made changes to their positions in the company. XTX Topco Ltd increased its stake in Cosmos Health by 52.1% in the fourth quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock valued at $50,000 after acquiring an additional 34,117 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Cosmos Health by 16.7% in the 1st quarter. Renaissance Technologies LLC now owns 390,500 shares of the company’s stock valued at $124,000 after purchasing an additional 55,925 shares in the last quarter. Finally, Citadel Advisors LLC boosted its holdings in shares of Cosmos Health by 133.1% in the 3rd quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock valued at $250,000 after purchasing an additional 128,776 shares in the last quarter. Institutional investors and hedge funds own 12.61% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cosmos Health in a research report on Monday, June 15th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Cosmos Health presently has an average rating of “Sell”.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.